State Street SPDR S&P Biotech ETF
292 hedge funds and large institutions have $3.09B invested in State Street SPDR S&P Biotech ETF in 2017 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 100 increasing their positions, 78 reducing their positions, and 48 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 6 → 12 (+6)
43% more capital invested
Capital invested by funds: $2.17B → $3.09B (+$922M)
40% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 48
28% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 78
9.07% more ownership
Funds ownership: 88.91% → 97.98% (+9.1%)
7% more funds holding
Funds holding: 274 → 292 (+18)
45% less call options, than puts
Call options by funds: $656M | Put options by funds: $1.19B
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$150M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$112M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$108M |
| 4 |
AssetMark Inc
Concord,
California
|
+$92.4M |
| 5 |
Citigroup
New York
|
+$68.2M |
Top Sellers
XBI Hedge Fund Activity: Q1 2017 in Review
292 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q1 2017, worth a combined $3.09B — up 43% from $2.17B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new XBI positions and 48 closed out — a net gain of 19 holders — while 100 added to existing stakes and 78 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $150M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $72.4M sold.
- 292 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q1 2017, up from 274 in Q4 2016.
- Funds reported $3.09B of State Street SPDR S&P Biotech ETF stock for Q1 2017, up 43% quarter-over-quarter.
- 67 funds opened new State Street SPDR S&P Biotech ETF positions in Q1 2017 and 48 closed out, a net change of +19 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q1 2017 was JP Morgan Chase, an estimated $150M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q1 2017 was Suvretta Capital Management, an estimated $72.4M sold.
Based on aggregated 13F filings for Q1 2017.